SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides gets USFDA nod to market generic cancer injection

16 Nov 2011 Evaluate

Drug firm Strides Arcolab has received approval from the UShealth regulator to market a generic carboplatin injection for the treatment ofovarian cancer. Onco Therapies, a wholly-owned subsidiary of the company, hasreceived United States Food and Drug Administration (USFDA) approval forCarboplatin injections. The approval by the USFDAis for carboplatin injections in strengths of 10 mg/mL, packaged in 50 mg/5 mL,150 mg/15 mL, 450 mg/45 mL and 600 mg/60 mL multi-dose vials. Carboplatinis part of the oncology portfolio licensed to Pfizer in January, 2010, for theUS market and is expected to be launched shortly. Accordingto IMS data of June 11, the US market for generic carboplatin is worth nearly$35 million.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×